Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease.
J Alzheimers Dis
; 49(4): 1123-34, 2016.
Article
em En
| MEDLINE
| ID: mdl-26639957
ABSTRACT
BACKGROUND:
Bapineuzumab, an anti-amyloid-ß monoclonal antibody, was evaluated in two placebo-controlled trials in APOE*É4 carriers and noncarriers, respectively, with Alzheimer's disease.OBJECTIVES:
A volumetric magnetic resonance imaging substudy was performed to determine if bapineuzumab altered brain volume rate of change.METHODS:
Bapineuzumab dosages included 0.5âmg/kg in carriers and 0.5 or 1.0âmg/kg in noncarriers, every 13 weeks for 78 weeks. Volumetric outcomes included annualized brain, ventricular, and mean hippocampal boundary shift integrals (BBSI; VBSI; HBSI) up to Week 71. Treatment differences were estimated using mixed models for repeated measures.RESULTS:
For BBSI and HBSI, there were no significant treatment-related differences within either study, but, compared to pooled carriers and noncarriers receiving placebo, noncarriers receiving1.0âmg/kg bapineuzumab had greater increases in these measures. Bapineuzumab-treated patients showed significantly greater VBSI rates compared with placebo for 0.5âmg/kg in carriers and 1.0âmg/kg (but not 0.5âmg/kg) in noncarriers.CONCLUSIONS:
Bapineuzumab produced an increase in ventricular volume compared with placebo. Etiology for this increase is unclear but may be related to amyloid-ß clearance or its consequences.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Encéfalo
/
Nootrópicos
/
Doença de Alzheimer
/
Anticorpos Monoclonais Humanizados
Tipo de estudo:
Clinical_trials
Limite:
Aged
/
Female
/
Humans
/
Male
Idioma:
En
Ano de publicação:
2016
Tipo de documento:
Article